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Background: Patients frequently report antibiotic allergies, however only 10% of labelled patients have a true 
allergy. 
Aim: We investigated the documentation of antibiotic “allergy” labels (AALs) and the effect of labelling on 
clinical outcomes, in a West Australian adult tertiary hospital. 
Methods: Retrospective cross-sectional analysis of patients captured in the 2013 and 2014 National 
Antimicrobial Prescribing Surveys.  Data was collected on documented antibiotic adverse drug reactions, 
antibiotic cost, prescribing appropriateness, prevalence of multi-drug resistant organisms, length of stay, 
intensive care admission, and readmissions.  
Results: Of 687 patients surveyed, 278 (40%) were aged 70 or above, 365 (53%) were male and 279 (41%) 
were prescribed antibiotics.  AALs were recorded in 122 (18%) patients and the majority were penicillin labels 
(n=87; 71%).  Details of AALs were documented for 80 of 141 (57%) individual allergy labels, with 61 
describing allergic symptoms.  Patients with beta-lactam allergy labels received fewer penicillins (p=0.0002) 
and more aminoglycosides (p=0.043) and metronidazole (p=0.021) than patients without beta-lactam labels.  
Five patients received an antibiotic that was contraindicated according to their allergy status.  Patients with 
AALs had significantly more hospital readmissions within 4 weeks (p=0.001) and 6 months (p=0.025) of 
discharge, compared with unlabelled patients.  The majority (81%) of readmitted labelled patients had major 
infections.  
Conclusions: AALs are common but poorly documented in hospital records.  Patients with AALs are 
significantly more likely to require alternative antibiotics, and hospital readmissions.  There may be a role for 
antibiotic allergy delabelling to mitigate the clinical and economic burdens for patients with invalid allergy 
labels. 



















Up to 20% of patients report one or more antibiotic allergies (antibiotic “allergy” labelled) (1-3).  However, the 
majority of antibiotic allergy labels (AALs) are invalid (4-6).  Drug allergy specialists can assist clinicians by 
delabelling many patients with alleged antibiotic allergies. For example, almost 90% of beta-lactam labels can 
be safely removed after thorough assessment (5,6).   
 
Beta-lactams, which comprise penicillins, cephalosporins, monobactams and carbapenems, currently account for 
60% of antibiotic prescriptions in Australian hospitals (7).  Avoiding beta-lactam or other antibiotics in patients 
with alleged allergy often necessitates prescription of second-line antibiotics which may be less effective, more 
expensive and lead to higher rates of adverse effects and multi-drug resistance (MDR) pathogens (4,8,9).  
International observational studies have shown that patients with AALs have increased hospital utilization and 
poorer clinical outcomes (10,11).  Unverified antibiotic allergy labelling is a significant and growing public 
health problem resulting in unnecessary adverse outcomes.  Whether systematic antibiotic allergy delabelling 
can mitigate these clinical and economic burdens remains to be seen.   
 
These issues have not been broadly addressed in an Australian context, apart from case series focusing on 
specific patient groups (12,13,14).  We sought to investigate the frequency of reported AALs, the accuracy of 
allergy documentation, appropriateness of antibiotic prescribing and the effect of labelling on clinical outcomes 
in an adult tertiary hospital in Western Australia.  
 
METHODS 
We performed a retrospective single-centre cross-sectional analysis of 775 inpatients in a 600-bed adult tertiary 
care teaching hospital in Perth, Western Australia.  All patients were captured in the 2013 and 2014 National 
Antimicrobial Prescribing Survey (NAPS), which was performed during “Antimicrobial Awareness Week” in 
November.  NAPS is a voluntary annual audit of Australian health services, led by The Australian Commission 










on Safety and Quality in Health Care (ACSQHC) which provides a point prevalence of hospital inpatient 
medication charts to assess volume and appropriateness of antimicrobial prescribing (15).   
 
NAPS data was collected from patients’ medication charts, by ward pharmacists.  The audit captured data on all 
patients admitted to hospital wards (including all medical and surgical specialties, intensive care unit, psychiatry 
and rehabilitation wards, but excluding the emergency department and day admission wards).  Data collected 
included patient demographics, antibiotics prescribed (at time of audit) and documented AALs.  AAL is a 
blanket term to denote any antibiotic recorded in the “allergies and adverse drug reaction” section of the 
patient’s medication chart.  Patients were excluded from the study if there was no NAPS documentation to 
indicate either the presence or absence of antibiotic adverse drug reactions.  For AALs, the culprit medication 
and alleged symptoms (if documented in the medication chart) were captured.  Documented AAL symptoms 
were classified as (1) anaphylaxis, (2) angioedema, (3) rash or unspecified swelling, (4) gastrointestinal upset, or 
(5) non-specific symptoms (e.g. headache).  Groups 1, 2 and 3 represent allergic-type symptoms (graded 
according to severity) and groups 4 and 5 represent probable non-immunological intolerances.  The daily costs 
of antibiotics were calculated, per patient, using the hospital pharmacy formulary.  NAPS prescribing scores are 
graded based on the degree of appropriateness (1 optimal; 2 adequate; 3 suboptimal; 4 inadequate; 5 not 
assessable) of antibiotic choice as assessed by an infectious diseases pharmacist or physician using an internally 
validated scoring system (15).  For the purposes of this study, scores of 1 or 2 were considered appropriate and 3 
or 4 as inappropriate.  Patient allergies were accounted for in the appropriateness scoring algorithms.  
Indications for each antibiotic prescription were classified as bacterial infection (specified), prophylaxis, or 
indication unclear.   
 
NAPS data was supplemented with electronic records and discharge summaries to record principal diagnosis of 
admission, admitting specialty unit, intensive care admissions, death during admission, hospital length of stay 
and readmissions within 4 weeks and 6 months of discharge.  The overall follow-up period for each patient, was 
6 months from inclusion (NAPS audit) date.  Direct hospital transfers, day procedures and review in the 
emergency department were not considered readmissions.  Patient electronic microbiology records were 
reviewed to capture any Clostridium difficile toxin, Methicillin-resistant Staphylococcus aureus (MRSA) and/or 
Vancomycin-resistant Enterococcus (VRE) positive screening or diagnostic microbiological samples.  
 










Study groups were classified based on the presence or absence of an AAL in the medication chart.  We further 
classified patients with an AAL into “beta-lactam” and “non-beta-lactam” labels.  We sub-classified “beta-
lactam” labels as “penicillin group”, “cephalosporin”, “carbapenem” or “monobactam” labels.  Patients were 
classified as non-allergic (no antibiotic allergy label; NAAL) if they had no known AAL or an allergy to a non-
antibiotic drug or non-drug allergen.  This study was approved through the Sir Charles Gairdner Group Human 
Research Ethics Committee (quality activity #8380). 
 
Statistical analysis 
Data were analysed using the R environment for statistical computing (16).  Medians and interquartile ranges 
(IQR) are presented for continuous variables whilst counts and percentages are presented for categorical 
variables, unless otherwise stated.  Chi-squared tests (Fisher’s exact tests where appropriate) were used to 
compare specific antibiotics prescribed and infections between beta-lactam allergic labelled patients and non-
beta-lactam allergic labelled patients.  Initially, binary logistic regression was used to analyse the relationships 
between demographic patient variables and any allergy label (event=‘Yes’).  Subsequently, multivariate models 
were conducted to investigate the effect of antibiotic allergy labelling on prevalence of highly resistant bacteria, 
intensive care admission, patient death in hospital and four-week readmission rate (logistic regression; 
event=‘Yes’); the number of readmissions within six months and NAPS prescribing score (ordinal logistic 
regression); hospital length of stay (Cox proportional hazards regression; event=“leaving hospital” where  those 
who died during their hospital stay are censored at their date of death); cost of antibiotics (linear regression, log-
transformed response); and the number of antibiotics prescribed (Poisson regression).  Patient age, gender, 
admitting team, antibiotic use and audit year were adjusted for in all models and backwards model selection was 
performed such that variables significant at a 5% level were retained for the final models. 
 
RESULTS 
A total of 775 patients were captured in the NAPS database (374 in 2013, 401 in 2014).  Based on the maximum 
available overnight hospital beds available, the capture rate was 79% in 2013 (374 out of 476 beds) and 89% in 
2014 (401 of 453 beds).  This is likely to be an underestimate, as not all beds were occupied at the time of the 
NAPS audits.  There were 38 instances where the same patient was recaptured due to ward transfer during the 
audit period.  The earliest capture date was used for these patients and an additional 50 patients were excluded 
because allergy status was not recorded in NAPS documentation.  The final cohort of 687 patients reflected the 










expected demographics in the tertiary care centre.  From 2013 to 2014 the mean age of all hospitalised patients 
was 61 years and 53% of patients were male.  In the final audit cohort, mean age was 62 years, 278 (40%) 
patients were aged 70 or above, 365 (53%) were male and 279 (41%) were prescribed antibiotics at the time of 
the audit (Table 1).  The major indications for antibiotics were pneumonia (n=74, 28%), genitourinary (n=44; 
17%), skin and soft tissue (n=42; 16%), intra-abdominal or gastrointestinal infections (n=34, 13%), and 
prophylaxis (n=26; 10%) (Table 2).  Prescribing scores were judged as appropriate for 176 of 279 prescriptions 
(63%), inappropriate for 84 (30%) and indeterminate for 19 (7%). 
 
Females and older patients were significantly more likely to have an AAL (gender: OR=2.54, 95% CI=1.69-
3.82, p<0.001; for a one standard deviation (19.6 years) increase in age: OR=1.31, 95% CI=1.06-1.60, p=0.007).  
The same was also true for beta-lactam AALs alone (gender: OR=2.28, 95% CI=1.46-3.54, p<0.001; for a one 
standard deviation increase in age: OR=1.33, 95% CI=1.07-1.67, p=0.011).  Patient admitting team (by 
individual specialties), audit year and prescription of antibiotics at the time of audit were not significantly 
associated with presence of AALs or, more specifically, beta-lactam AALs. 
 
Antibiotic allergy “labels” 
One or more AALs were recorded in 122 (18%) patients, with NAAL recorded for the remaining 565 (82%) 
patients.  The majority of AALs were beta-lactam labels (n=101; 83%), of which most were in the “penicillin 
group” (n=87; 71% of “allergic” cohort; 13% of whole cohort).  The specific AALs comprising the beta-lactam 
group were “penicillin (not otherwise specified)” (n=76; 75%), “cephalexin” (n=7), “amoxicillin” (n=5), 
“amoxicillin/clavulanic acid” (n=3), “piperacillin/tazobactam” (n=2) and “cephazolin” (n=2).  The majority of 
non-beta-lactam labels comprised the sulfamethoxazole/trimethoprim (n=11), macrolide (n=7) and glycopeptide 
(vancomycin) (n=7) groups.  In the AAL group, 108 (89%) patients had a single allergy, 10 (8%) had two 
documented AALs, and 4 (3%) had three or more labels.   
 
Descriptions of reactions to the culprit antibiotic were documented for 80 of 141 (57%) individual AALs.  For 
the remaining 61 (43%) labels there was no documentation of symptoms.  Of the 80 AALs with documentation, 
61 described symptoms consistent with allergy and 19 were non-specific (non-allergic) intolerances (Figure 1). 
Non-specific symptoms were more frequently recorded for non-beta-lactam labels.   











Five patients, among a group of 33 penicillin-labelled patients prescribed antibiotics (6% of the 87 penicillin 
labelled patients in total), were receiving an antibiotic that would be considered contraindicated according to 
their allergy status.  Two patients with a history of unspecified penicillin-induced anaphylaxis received a 
penicillin (piperacillin/tazobactam; amoxicillin/clavulanic acid).  One patient with unspecified penicillin-
induced “rash” received piperacillin/tazobactam.  Two patients with AAL documented as “unknown reaction” 
(one to an unspecified penicillin, the other to amoxicillin/clavulanic acid), received amoxicillin.  There were no 
adverse events captured as a result of these prescriptions, although this study was not designed to assess 
outcomes of prescribing errors. 
 
Impact of antibiotic allergy label on choice of antibiotics 
The impact of antibiotic allergy labels on antibiotic prescriptions is summarised in Table 2.  As expected, 
patients with beta-lactam AALs were prescribed significantly fewer penicillins (p=0.0002) and significantly 
more alternative antibiotics such as aminoglycosides (p=0.043) and metronidazole (p=0.021), than non-beta-
lactam labelled patients.  Although there was increased use of 3rd and 4th generation cephalosporins, quinolones, 
clindamycin, fusidic acid and daptomycin, among beta-lactam labelled patients, this did not reach statistical 
significance. 
 
Impact of antibiotic allergy label on hospital outcomes 
Of the 663 discharged patients (excluding 24 patients who died in hospital), 129 (19.5%) were readmitted within 
four weeks.  Patients with an AAL were significantly more likely to be readmitted within four weeks than 
NAAL patients (OR=2.16, 95% CI=1.34-3.46, p=0.001) (Table 3).  Of the 35 AAL patients readmitted within 
four weeks, 29 (81%) had infections in the first and/or second admission (captured as principal diagnosis or 
NAPS antibiotic prescription).  Five patients (14%) were readmitted with recurrence of the same infection 
(urosepsis, pneumonia, wound and ocular infections).  Limiting the cohort to patients with a principal diagnosis 
of infection, 9 of 30 (30%) AAL patients were readmitted within four weeks, compared with 24 of 136 (18%) 
NAAL, although this did not reach statistical significance, and was therefore not included in the final 
multivariate model. 
 










Patients with an AAL also had significantly more readmissions within six months compared to NAAL patients 
(OR=1.55, 95% CI=1.06-2.27, p=0.025) (Table 3).  Specifically, 58 of 121 (48%) AAL patients were readmitted 
in six months compared with 200 of 542 (37%) NAAL patients.  Furthermore, 34 (28%) AAL patients were 
readmitted twice or more in this period, compared with 102 (18%) NAAL patients.   
 
Further analysis focussing on beta-lactam labelled patients yielded corresponding results.  Beta-lactam labelled 
patients were significantly more likely to require readmission within 4 weeks with 29 of 101 (29%) beta-lactam 
AAL patients readmitted, compared with 100 of 562 (18%) of non-beta-lactam AAL patients (OR=2.03, 95% 
CI=1.23-3.35, p=0.006).  The length of readmissions ranged from 2 to 22 days.  Beta-lactam AAL patients also 
had significantly more readmissions within 6 months (OR=1.51, 95% CI=1.00-2.27, p=0.049).  Thirty of 101 
(30%) beta-lactam AAL patients had two or more readmissions within 6 months, compared with 106 of 562 
(19%) of non-beta-lactam AAL patients. 
 
These results were adjusted for patient age, gender, admitting team and intensive care admissions and no 
specific chronic diseases (e.g. cystic fibrosis, malignancy, transplant recipients) appeared overrepresented 
among readmitted allergy labelled patients.  There were no significant differences in the following variables 
between patients with and without any antibiotic allergy labels: antibiotic costs, appropriateness of antibiotic 
prescribing, prevalence of multi-drug resistant organisms on microbiological follow-up, hospital length of stay, 
patient death in hospital and intensive care admissions (Table 3). 
 
DISCUSSION 
This study provides a snapshot of antibiotic allergy labelling in a metropolitan tertiary care centre.  Eighteen per 
cent of hospitalized patients reported at least one AAL, the majority to penicillin (72%).  This equals the 
national average (18%) and is toward the upper range of reports in the international literature (1-3,8).   
 
Documentation of “allergic” symptoms was frequently missing from patient medication charts, despite inpatient 
status and ward pharmacist review.  Furthermore, five (6%) penicillin labelled patients received antibiotics 
which would be considered contraindicated, according to their allergy status.  A recently published Australian 
study reported a similar rate of inadvertent antibiotic rechallenge (7%) in a general medical cohort (14).  This is 










concerning in light of reports of increasing medication-related anaphylaxis and mortality in adult Australian 
hospitals (17,18).  The ACSQHC medication safety standards state such medication errors are “highly 
preventable” through effective use of allergy alert systems (19).  However, allergy alert systems rely on accurate 
allergy documentation and correct clinical decision making: deficits in both areas have been highlighted in 
previous studies (20,21).  None of the five patients had adverse reactions following penicillin re-challenge.  
Multiple factors (including loss of IgE-mediated allergy reactivity over time and labelling non-immunological 
ADRs or viral-induced exanthems) explain why many labelled patients tolerate future penicillin use (4,5,6).  
However, appropriate risk stratification is essential to avoid preventable prescribing errors and harm to truly 
allergic patients.  It is not clear whether further (undocumented) history guided clinical decision-making for the 
five patients highlighted in this study.   
 
Drug allergy specialists can safely investigate IgE-mediated (Type I) allergy labels through thorough clinical 
assessment with skin-prick/intradermal testing, and observed oral challenges for selected cases (22,24).  This 
enables confirmation or, in most cases, exclusion (i.e. delabelling) of AALs.  There is evidence supporting the 
safety of supervised graded oral amoxicillin challenges for children with historical immediate or non-immediate 
reactions to penicillin, but this approach remains to be fully investigated in the adult population (25).  In the 
acute setting, desensitization may be indicated to induce temporary drug tolerance for patients with true IgE-
mediated antibiotic allergy, where no acceptable alternative antibiotic exists (23).  Testing strategies for delayed 
T cell mediated (Type IV) reactions include patch testing (which is only available at select drug allergy clinics 
in Australia) and oral challenges on a case-by-case basis (22,24). 
 
To our knowledge this is the largest Australian-based study to show that hospitalized patients carrying an AAL 
have poorer clinical outcomes, compared with unlabelled patients.  Our study is strengthened by the unbiased 
selection criteria (based on the NAPS) which provided a “real life” snapshot of documentation and prescribing 
for patients with AALs at the time of their admission.  Limitations of our study include the reliance on 
documentation in medical records to collect additional data.  However, we used objective clinical outcomes such 
as in-hospital mortality, length of stay and readmissions, which are accurately reflected in medical records.  Due 
to the cross-sectional retrospective study design it was not possible to determine the validity of reported AALs 
(by patient interview or specific allergy testing) to further classify via a strict immunological basis.  
Furthermore, we could not capture every infection or antimicrobial prescription during admission, which limited 










sub-analyses in these groups.  Nevertheless, the same trend towards frequent readmissions was seen when 
limiting the cohort to patients with a principal diagnosis of infection, or those prescribed antibiotics.  Our results 
may have been biased by the large proportion of beta-lactam AAL patients.  However, this reflects the usual 
composition of AALs in the hospital setting, and encouragingly, delabelling strategies have been well validated 
in this cohort.   
 
We propose that the association between AALs and hospital readmissions is best explained by necessary 
reliance on second-line antibiotics in labelled patients with infections.  Our data (Table 2) highlights the 
differences in antibiotic prescribing patterns between AAL and NAAL groups, with greater reliance on 
alternative antibiotics for AAL patients.  Second-line therapies have less favourable safety profiles and can be 
resistance and Clostridum difficile generating; all of which, may necessitate hospital readmissions (6,10,26).  An 
alternative interpretation is that patients prone to readmissions for other reasons (such as more severe disease 
states requiring more frequent repetitive courses or high dose parenteral antibiotics) accumulate more drug 
allergy labels over time.  Although it is not possible to discount the latter, our statistical analysis indicated that 
patient age, gender, admitting specialty, intensive care admission and chronic disease states, did not affect the 
results.  
 
This study adds to a growing international body of literature highlighting the significant public health 
implications of (frequently invalid) AALs (5,6,8-14,27).  Our study complements findings from two recently 
published studies (14,28).  A Dutch study reported a higher risk of readmissions within 12 weeks among 
penicillin allergy labelled patients (28).  An Australian study reported poor AAL documentation, and 
inappropriate antibiotic prescriptions for some AAL patients (14).  Both studies reported increased use of broad 
spectrum antibiotics (including 3rd generation cephalosporins, quinolones and macrolides) for AAL patients 
(14).  Similar findings have been reported in the United States; Macy et al reported that patients with penicillin 
allergy labels spend significantly more time in hospital, with exposure to more broad-spectrum antibiotics and 
higher rates of C. difficile, MRSA and VRE (11).  Another large American study reported increased lengths of 
stay, intensive care admission rates and higher mortality rates for patients with AALs (10).  Economic 
modelling suggests that delabelling strategies could lead to significant health care savings (11).  In our study 
there were no significant differences in antibiotic costs, hospital length of stay, and intensive care admissions.  














Clinicians face two conflicting issues when managing patients with AALs.  In the acute setting, clinicians must 
pay AALs respect by carefully documenting labels and prescribing antibiotics safely.  However, in the long-
term, over-labelling can set up a negative cycle of restricted access to antibiotics, poorer clinical outcomes and 
increased hospitalisation - the “revolving door”.  Given that the majority of AALs are in fact, invalid, many 
patients may be unnecessarily suffering adverse outcomes.  Clinical education in both primary care and hospital 
settings could lead to considerable improvements in diagnosis and management of patients with suspected drug 
allergy.  Optimal drug allergy management relies on contemporaneous, detailed ADR reporting, to differentiate 
immunological (type I-IV) and non-immunological ADRs at the outset.  Patients who carry a historically 
plausible allergy label (particularly beta-lactam labels), can be further assessed by a drug allergy specialist to 
confirm true allergy labels and remove invalid labels.  Ultimately, a collaborative effort to improve system-wide 
antibiotic allergy management could lead to significant health care savings and provide patients with more 
timely, safe and effective care. 
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toms associated with antibiotic labels, per total antibiotic allergy labels.  
 
 














Table 1: Counts and percentages of patient demographics 
Demographics Any antibiotic allergy label All patients  
(N=687) Yes (N=122) No (N=565) 
Age Group 
<30 yrs 9 (18%) 41 50 (7%) 
30-49 yrs 14 (10%) 121 135 (20%) 
50-69 yrs 37 (17%) 187 224 (33%) 
70-89 yrs 54 (22%) 187 241 (35%) 
> 90 yrs 8 (22%) 29 37 (5%) 
Gender 
Female 80 (25%) 242 322 (47%) 
Male 42 (12%) 323 365 (53%) 
Admitting Team 
Medical 77 (20%) 301 378 (55%) 
Surgical 32 (15%) 187 219 (32%) 
ICU / Psychiatry 13 (14%) 77 90 (13%) 
Principal Diagnosis 
Infection 30 (17%) 142 172 (25%) 
Other (Not infection) 92 (18%) 423 515 (75%) 
Prescribed antibiotics at time of audit 
No 74 (18%) 334 408 (59%) 



























Table 2: Counts and percentages of specific antibiotics prescribed, and documented bacterial infections, broken down by antibiotic allergy 
label (note some patients received more than one antibiotic prescription or had more than infection) 
Antibiotic prescriptions and 
infections by allergy label 
(N=279) 
Any antibiotic allergy label 
No antibiotic allergy 
label (N=231) P-Value^ Any beta-lactam 
allergy label (N=41) 
 
Other antibiotic 
allergy label (N=7) 
 
Antibiotics prescribed at time of audit  
Penicillins (penicillin V & G) 0 (0.0%) 1 (14.3%) 9 (3.9%) NS 
Amoxycillin +/- clavulanic acid 3 (7.3%) 1 (14.3%) 31 (13.4%) NS 
Flucloxacillin 1 (2.4%) 0 (0.0%) 14 (6.1%) NS 
Piperacillin/tazobactam 5 (12.2%) 2 (28.6%) 68 (29.4%) 0.022 
All penicillins (all above)  9 (22.0%) 4 (57.1%) 122 (52.8%) 0.0002 
Carbapenems 3 (7.3%) 0 (0.0%) 9 (3.9%) NS 
1st generation cephalosporins 8 (19.5%) 2 (28.6%) 41 (17.8%) NS 
 3rd / 4th generation 
cephalosporins 6 (14.6%) 1 (14.3%) 13 (5.6%) NS 
All beta-lactams (all above) 26 (63.4%) 7 (100.0%) 185 (80.1%)   0.013 
Macrolides 3 (7.3%) 0 (0.0%) 25 (10.8%) NS 
Quinolones 7 (17.1%) 0 (0.0%) 27 (11.7%) NS 
Metronidazole 7 (17.1%) 0 (0.0%) 14 (6.1%) 0.021 
Norfloxacin 1 (2.4%) 0 (0.0%) 10 (4.3%) NS 
Sulfonamides 0 (0.0%) 0 (0.0%) 9 (3.9%) NS 
Tetracyclines 1 (2.4%) 0 (0.0%) 5 (2.2%) NS 
Trimethoprim 2 (4.9%) 0 (0.0%) 4 (1.7%) NS 
Aminoglycosides 3 (7.3%) 0 (0.0%) 3 (1.3%) 0.043 
Rifaximin 1 (2.4%) 0 (0.0%) 2 (0.9%) NS 
Cotrimoxazole 0 (0.0%) 0 (0.0%) 1 (0.4%) NS 
Nitrofurantoin 0 (0.0%) 0 (0.0%) 1 (0.4%) NS 
Vancomycin 2 (4.9%) 0 (0.0%) 21 (9.1%) NS 
Clindamycin 3 (7.3%) 0 (0.0%) 6 (2.6%) NS 
Fusidic acid or daptomycin 1 (2.4%) 0 (0.0%) 2 (0.9%) NS 
Anti-mycobacterial agents  1 (2.4%) 0 (0.0%) 4 (1.7%) NS 
Documented bacterial infections 
Pneumonia 12 (29.3%) 1 (14.3%) 61 (26.4%) NS 
Genitourinary 4 (9.8%) 1 (14.3%) 40 (17.3%) NS 
Skin 10 (24.4%) 0 (0.0%) 33 (14.3%) NS 
Intra-abdominal 3 (7.3%) 0 (0.0%) 20 (8.7%) NS 
Osteomyelitis / joint 2 (4.9%) 0 (0.0%) 19 (8.2%) NS 
Gastrointestinal 3 (7.3%) 0 (0.0%) 8 (3.5%) NS 
Bacteraemia 0 (0.0%) 0 (0.0%) 7 (3.0%) NS 
Febrile neutropenia 2 (4.9%) 0 (0.0%) 5 (2.2%) NS 
CNS 0 (0.0%) 1 (14.3%) 3 (1.3%) NS 
Other infection 1 (2.4%) 0 (0.0%) 8 (3.5%) NS 
Prophylaxis 4 (9.8%) 1 (14.3%) 22 (9.5%) NS 
Indication unclear 1 (2.4%) 3 (42.9%) 14 (6.1%) NS 
^Fisher’s exact test: comparing beta-lactam labelled patients with all other patients 













Table 3: Summary statistics of patient outcomes broken down by any antibiotic allergy label 
Outcomes Any antibiotic allergy label P-Value 
Yes No 
Length of stay 10 (5 – 21) days  13 (6 - 27) days NS 
Death during admission 1 (1%) 23 (4%) NS 
Readmission within 4 weeks 35 (29%) 94 (17%) 0.001 
Readmission in 6 months 24 (20%) 98 (18%) 0.025 
Cost of prescribed antibiotics 
per patient day* 
$5 ($1-$32) $10 ($1-$28) NS 
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